Home Cart Sign in  
Chemical Structure| 941685-37-6 Chemical Structure| 941685-37-6

Structure of Ruxolitinib (S enantiomer)
CAS No.: 941685-37-6

Chemical Structure| 941685-37-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

S-Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, > 130-fold selectivity for JAK1/2 versus JAK3.

Synonyms: S-INCB18424; S-Ruxolitinib; (S)-INCB018424

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ruxolitinib (S enantiomer)

CAS No. :941685-37-6
Formula : C17H18N6
M.W : 306.37
SMILES Code : N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2
Synonyms :
S-INCB18424; S-Ruxolitinib; (S)-INCB018424
MDL No. :MFCD13184797
InChI Key :HFNKQEVNSGCOJV-HNNXBMFYSA-N
Pubchem ID :50878566

Safety of Ruxolitinib (S enantiomer)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Ruxolitinib (S enantiomer)

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Description
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is an orally active, potent JAK inhibitor that is the S-enantiomer of Ruxolitinib[1][2].
Target
  • JAK1

    JAK1, IC50:3.3 nM

  • Tyk2

    TYK2, IC50:19 nM

  • JAK2

    JAK2, IC50:2.8 nM

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice unilateral ureteral obstruction (UUO) Oral gavage 30 mg/kg twice daily for 14 days Ruxolitinib treatment alleviated UUO-induced renal damage, inflammation, oxidative stress and apoptosis. PMC6949153

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03697460 Lichen Planus PHASE2 COMPLETED 2020-08-25 Mayo Clinic in Arizona, Scotts... More >>dale, Arizona, 85259, United States Less <<
NCT00674479 Acute Myeloid Leukemia|Acute L... More >>ymphocytic Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia Less << PHASE2 COMPLETED 2017-03-23 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.26mL

0.65mL

0.33mL

16.32mL

3.26mL

1.63mL

32.64mL

6.53mL

3.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories